Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Rare diseases focused Mereo BioPharma said it had been granted a fast-track designation by the US Food and Drug Administration for an ovarian cancer treatment.
The status was given to navicixizumab for the treatment of high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who had received at least three prior therapies and/or prior bevacizumab.
Navicixizumab was an anti-DLL4/VEGF bispecific antibody and one of two product candidates Mereo acquired through its April 2019 merger with OncoMed Pharmaceuticals.
At 1:10pm: (LON:MPH) Mereo Biopharma Group Ltd share price was +6p at 65.5p